ConductScience.org, home

Trial · NCT03399786

Outcomes17

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYPercent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand)Week 24Percent ChangeLEAST_SQUARES_MEAN
SECONDARYPercent Change in Apolipoprotein B (Apo B) From Baseline to Week 24 (ITT Estimand)Week 24Percent ChangeLEAST_SQUARES_MEAN
SECONDARYPercent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 24 (ITT Estimand)Week 24Percent ChangeLEAST_SQUARES_MEAN
SECONDARYPercent Change in Total Cholesterol (TC) From Baseline to Week 24 (ITT Estimand)Week 24Percent ChangeLEAST_SQUARES_MEAN
SECONDARYPercentage of Participants With ≥30% Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (ITT Estimand)At Week 24Percentage of ParticipantsNUMBER
SECONDARYPercentage of Participants With ≥50% Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (ITT Estimand)At Week 24Percentage of ParticipantsNUMBER
SECONDARYAbsolute Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (ITT Estimand)Week 24Milligrams per Deciliter (mg/dL)LEAST_SQUARES_MEAN
SECONDARYPercentage of Participants Who Met United States (US) Apheresis Eligibility Criteria at Week 24 (ITT Estimand)At Week 24Percentage of ParticipantsNUMBER
SECONDARYPercentage of Participants With Low-Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter (mg/dL) (2.59 Millimoles Per Liter [mmol/L]) at Week 24 (ITT Estimand)At Week 24Percentage of ParticipantsNUMBER
SECONDARYPercentage of Participants Who Met European Union (EU) Apheresis Eligibility Criteria at Week 24 (ITT Estimand)At Week 24Percentage of ParticipantsNUMBER
SECONDARYPercentage of Participants With Calculated Low-Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL (1.81 mmol/L) at Week 24 (ITT Estimand)At Week 24Percentage of ParticipantsNUMBER
SECONDARYPercent Change in Fasting Triglycerides (TG) From Baseline to Week 24 (ITT Estimand)Week 24Percent ChangeLEAST_SQUARES_MEAN
SECONDARYPercent Change in Lipoprotein A (Lp[a]) From Baseline to Week 24 (ITT Estimand)Week 24Percent ChangeLEAST_SQUARES_MEAN
SECONDARYAbsolute Change in Apolipoprotein B (Apo B) From Baseline to Week 24 (ITT Estimand)Week 24mg/dLLEAST_SQUARES_MEAN
SECONDARYAbsolute Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 24 (ITT Estimand)Week 24mg/dLLEAST_SQUARES_MEAN
SECONDARYAbsolute Change in Total Cholesterol (TC) From Baseline to Week 24 (ITT Estimand)Week 24mg/dLLEAST_SQUARES_MEAN
SECONDARYPercent Change in Apolipoprotein CIII (Apo CIII) From Baseline to Week 24 (ITT Estimand)Week 24Percent ChangeLEAST_SQUARES_MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03399786/outcomes